BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol 2010;52:296-304. [PMID: 20006399 DOI: 10.1016/j.jhep.2009.11.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Cong Y, Shi B, Lu Y, Wen S, Chung R, Jin D. One-step Conjugation of Glycyrrhetinic Acid to Cationic Polymers for High-performance Gene Delivery to Cultured Liver Cell. Sci Rep 2016;6:21891. [PMID: 26902258 DOI: 10.1038/srep21891] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
2 Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Cao S, Zhu S, Yin W, Xu H, Wu J, Wang Q. Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization. Onco Targets Ther 2020;13:9407-17. [PMID: 33061427 DOI: 10.2147/OTT.S257271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Dufour JF. TACE with or without systemic therapy? J Hepatol. 2012;56:1224-1225. [PMID: 22402292 DOI: 10.1016/j.jhep.2012.02.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
5 Feng Z, Ye Z, Xie J, Chen W, Li W, Xing C. Study on the mechanism of LOXL1-AS1/miR-3614-5p/YY1 signal axis in the malignant phenotype regulation of hepatocellular carcinoma. Biol Direct 2021;16:24. [PMID: 34863279 DOI: 10.1186/s13062-021-00312-8] [Reference Citation Analysis]
6 Ma D, Shen B, Seewoo V, Tong H, Yang W, Cheng X, Jin Z, Peng C, Qiu W. GADD45β induction by S-adenosylmethionine inhibits hepatocellular carcinoma cell proliferation during acute ischemia-hypoxia. Oncotarget 2016;7:37215-25. [PMID: 27177086 DOI: 10.18632/oncotarget.9295] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
7 Severi T, van Malenstein H, Verslype C, van Pelt JF. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010;31:1409-20. [PMID: 20953207 DOI: 10.1038/aps.2010.142] [Cited by in Crossref: 115] [Cited by in F6Publishing: 104] [Article Influence: 9.6] [Reference Citation Analysis]
8 Zhao Y, Xue F, Sun J, Guo S, Zhang H, Qiu B, Geng J, Gu J, Zhou X, Wang W, Zhang Z, Tang N, He Y, Yu J, Xia Q. Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma. Clin Epigenetics 2014;6:30. [PMID: 25859288 DOI: 10.1186/1868-7083-6-30] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
9 Heuman DM, Gilles HS, Solomon C, Bajaj JS. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? No. Eur J Intern Med. 2012;23:37-39. [PMID: 22153529 DOI: 10.1016/j.ejim.2011.09.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
10 Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: Implications for imaging and management. Radiology. 2011;258:673-693. [PMID: 21339346 DOI: 10.1148/radiol.10100376] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
11 Chen T, Zhu C, Wang X, Pan Y. LncRNA ELF3-AS1 is a Prognostic Biomarker and Correlated with Immune Infiltrates in Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:8323487. [PMID: 34336727 DOI: 10.1155/2021/8323487] [Reference Citation Analysis]
12 Zhang Y, Hu D, Han S, Yan G, Ma C, Wei C, Yu M, Li D, Sun Y. Preparation and evaluation of reduction-responsive nano-micelles for miriplatin delivery. Exp Biol Med (Maywood) 2016;241:1169-76. [PMID: 26743756 DOI: 10.1177/1535370215625473] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
13 Chen H, Li M, Wan T, Zheng Q, Cheng M, Huang S, Wang Y. Design and synthesis of dual-ligand modified chitosan as a liver targeting vector. J Mater Sci Mater Med 2012;23:431-41. [PMID: 22105225 DOI: 10.1007/s10856-011-4494-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
14 Zhang RK, Liu JL. Screening the genome for HCC-specific CpG methylation signatures as biomarkers for diagnosis and prognosis evaluation. BMC Med Genomics 2021;14:163. [PMID: 34147096 DOI: 10.1186/s12920-021-01015-9] [Reference Citation Analysis]
15 Radu P, Dufour JF. Changing TACTICS in intermediate HCC: TACE plus sorafenib. Gut 2020;69:1374-6. [PMID: 32169908 DOI: 10.1136/gutjnl-2020-320692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Majumder S, Piguet AC, Dufour JF, Chatterjee S. Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol. 2013;705:86-95. [PMID: 23454556 DOI: 10.1016/j.ejphar.2013.02.026] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
17 Dufour J, Bargellini I, De Maria N, De Simone P, Goulis I, Marinho R. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Annals of Oncology 2013;24:24-9. [DOI: 10.1093/annonc/mdt054] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
18 Yu SJ, Yoon J. Molecular targeted therapy with transarterial chemoembolization. Gastrointestinal Intervention 2013;2:78-81. [DOI: 10.1016/j.gii.2013.09.012] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Baffy G. Hepatocellular Carcinoma in Obesity: Finding a Needle in the Haystack? In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 63-77. [DOI: 10.1007/978-981-10-8684-7_6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Martin J, Dufour JF. Abnormal nitrosothiol metabolism in hepatocellular carcinoma. J Hepatol 2011;54:579-80. [PMID: 21112114 DOI: 10.1016/j.jhep.2010.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Ammerpohl O, Pratschke J, Schafmayer C, Haake A, Faber W, von Kampen O, Brosch M, Sipos B, von Schönfels W, Balschun K. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer. 2012;130:1319-1328. [PMID: 21500188 DOI: 10.1002/ijc.26136] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 5.8] [Reference Citation Analysis]
22 Hu P, Cui H, Lei T, Li S, Mai E, Jia F. Linc00511 Indicates A Poor Prognosis Of Liver Hepatocellular Carcinoma. Onco Targets Ther 2019;12:9367-76. [PMID: 31807017 DOI: 10.2147/OTT.S228231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Blum HE. Individualized medicine 2010. J Cell Mol Med 2010;14:2257-63. [PMID: 20731747 DOI: 10.1111/j.1582-4934.2010.01155.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Chen Q, Sun Y, Wang J, Yan G, Cui Z, Yin H, Wei H. Preparation and characterization of glycyrrhetinic acid-modified stearic acid-grafted chitosan micelles. Artificial Cells, Nanomedicine, and Biotechnology 2013;43:217-23. [DOI: 10.3109/21691401.2013.845570] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15:1198-1204. [PMID: 21036880 DOI: 10.1634/theoncologist.2010-0180] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
26 Kong Q, Liang C, Jin Y, Pan Y, Tong D, Kong Q, Zhou J. The lncRNA MIR4435-2HG is upregulated in hepatocellular carcinoma and promotes cancer cell proliferation by upregulating miRNA-487a. Cell Mol Biol Lett 2019;24:26. [PMID: 30988676 DOI: 10.1186/s11658-019-0148-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]